Holen Sie sich die Stockscreener-App
3.4158
4.67%
-0.0742
Schlusskurs vom Vortag:
$3.49
Offen:
$3.61
24-Stunden-Volumen:
100.25K
Relative Volume:
0.39
Marktkapitalisierung:
$228.62M
Einnahmen:
$7.69M
Nettoeinkommen (Verlust:
$-17.65M
KGV:
-9.1258
EPS:
-0.3743
Netto-Cashflow:
$-15.72M
1W Leistung:
-9.84%
1M Leistung:
-19.05%
6M Leistung:
+9.08%
1J Leistung:
+33.08%
1-Tages-Spanne:
$3.32
$3.69
1-Wochen-Bereich:
$3.32
$3.85
52-Wochen-Spanne:
$1.30
$4.85
Adagene Inc Adr Stock (ADAG) Company Profile
Compare ADAG vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
3.405 | 234.33M | 7.69M | -17.65M | -15.72M | -0.3743 |
VRTX
Vertex Pharmaceuticals Inc
|
521.27 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.21 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,006.01 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.71 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.29 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Guggenheim | Buy |
| 2025-08-06 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | Eingeleitet | China Renaissance | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Adagene Inc Adr Aktie (ADAG) Neueste Nachrichten
Adagene Secures Milestone Payments in Exelixis SAFEbody ADC Collaboration - TipRanks
Cancer drug milestone brings new cash to Adagene (NASDAQ: ADAG) - Stock Titan
A cancer-drug milestone brings Adagene a $2 million payment - Stock Titan
Adagene Stock Price Forecast. Should You Buy ADAG? - StockInvest.us
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Barchart.com
Adagene (NASDAQ: ADAG) officer to sell 131K ADS to cover option taxes - Stock Titan
Adagene to Participate in Three Upcoming Investor Conferences - GlobeNewswire
Adagene (NASDAQ: ADAG) officer plans August ADS sell-to-cover - Stock Titan
Adagene (ADAG): WuXi PharmaTech and WuXi AppTec disclose 3.5% beneficial stake - Stock Titan
Adagene Inc. (Nasdaq: ADAG) boosts cash to US$127.9M and updates H1 2026 results - Stock Titan
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates - Yahoo Finance
Adagene’s Cancer Trial Results Expected in 1H 2027 - Stock Titan
Adagene (NASDAQ:ADAG) CEO Peter Luo Acquires 22,966 Shares - MarketBeat
Exome Asset Management LLC Decreases Holdings in Adagene Inc. Sponsored ADR $ADAG - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Adagene (ADAG) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary - Quartr
Guggenheim reiterates Adagene stock Buy rating on competitor shift - Investing.com
ADAG Stock Price, Quote & Chart - ChartMill
Adagene (ADAG) Stifel 2026 Targeted Oncology Virtual Forum Summary - Quartr
Adagene Discloses Preliminary US$127.9 Million Cash Balance as of June 30, 2026 - The Globe and Mail
Adagene (ADAG) reports preliminary US$127.9M cash balance in June 2026 6-K - Stock Titan
ADAG - Finviz
Adagene, Inc. Sponsored ADR Actuals & Estimates (NASDAQ:ADAG) - TradingView
Adagene (ADAG) upgraded to buy: Here's what you should know - MSN
Adagene (NASDAQ: ADAG) Schedule 13D/A details Luo group and trust stakes - Stock Titan
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Guggenheim raises Adagene stock price target on cancer drug data - Investing.com
Are medical stocks lagging Adagene (ADAG) this year? - MSN
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Adagene spotlights ADG126 strategy as masked CTLA-4 trial advances in colorectal cancer - MSN
Adagene Inc. (ADAG) Presses Lower: Support Test in Sight After 1.88% DeclineTriple EMA - dars.gov.et
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer - sharewise.com
WuXi entities report 3.49M-share stake in Adagene (NASDAQ: ADAG) - Stock Titan
Adagene Inc. to Participate in Stifel Annual Virtual Oncology Event and Jefferies Global Healthcare Conference - Quiver Quantitative
Adagene to Participate in Two Upcoming Investor Conferences - marketscreener.com
Janus Henderson (ADAG) reports 6.67M ADRs, 10.1% stake (04/30/2026) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT) - The Globe and Mail
Adagene announces pricing of $70M public offering of ADS - MSN
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat
Adagene and Incyte Partner to Develop Colorectal Cancer Therapy - HarianBasis.co
Qinghai Zhao Net Worth (2026) - GuruFocus
Adagene reports trial data for cancer drug muzastotug combos By Investing.com - Investing.com South Africa
Adagene reports trial data for cancer drug muzastotug combos - Investing.com
Experimental Adagene drug lifts liver cancer response to 66.7% - Stock Titan
Adagene (NASDAQ: ADAG) shows strong AACR 2026 data for muzastotug combo therapies - Stock Titan
Adagene Presents Two Posters at AACR 2026 with New Data - GlobeNewswire
Adagene Looks Attractive With ADG126 And Validating Partnerships (NASDAQ:ADAG) - Seeking Alpha
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Adagene appoints Peter Lebowitz to advisory board - Investing.com
Adagene appoints Peter Lebowitz to advisory board By Investing.com - Investing.com India
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - Bitget
Finanzdaten der Adagene Inc Adr-Aktie (ADAG)
Umsatz
Nettogewinn
Free Cashflow
ENV
Adagene Inc Adr-Aktie (ADAG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DO CUONG V | Director |
Aug 14 '26 |
Buy |
3.75 |
2,000 |
7,500 |
2,000 |
| Luo Peter | Chief Executive Officer |
Aug 04 '26 |
Buy |
3.65 |
22,966 |
83,746 |
67,966 |
| Luo Peter | Chief Executive Officer |
Aug 05 '26 |
Buy |
3.65 |
279 |
1,018 |
68,245 |
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):